UNCY
Unicycive Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.52
+4.61%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -83.7%
- EBIT
- -8.8%
- EPS
- +43.0%
- Free cash flow
- +16.1%
- Operating cash flow
- +16.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +175.7%
- EPS
- +140.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- +28.5%
- EBIT
- +8.1%
- Net income
- +27.7%
- EPS
- +70.4%
- Free cash flow
- -9.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026